Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms

Immunologic Research

Volumn 46, Issue 1-3, 2010, Pages 192-205

  Riaz, Wasif ^a   Hernandez Ilizaliturri, Francisco J ^a   Czuczman, Myron S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cytokines and interleukins; Monoclonal antibodies; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

BENDAMUSTINE; BISPECIFIC ANTIBODY; CARBOPLATIN; CD20 ANTIBODY; COLONY STIMULATING FACTOR 1; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; LENALIDOMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HEX A20; OFATUMUMAB; POMALIDOMIDE; PREDNISONE; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOPENIA; DRUG DOSE ESCALATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; FUCOSYLATION; GENETIC ENGINEERING; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFECTION; INNATE IMMUNITY; LARGE CELL LYMPHOMA; LEUKAPHERESIS; LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA; NATURAL KILLER CELL; NEUTROPHIL; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, NON-HODGKIN;

EID: 77949423291     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-009-8121-x     Document Type: Review

References (83)

1. Jemal A, Seigel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225-49.
2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphoma. Clinical features of major subtypes. J Clin Oncol. 1998;16:2780-95.
3. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosinekinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7.
4. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-7.
5. Barinaga M. From bench top to bedside. Science. 1997;278:1036-9.
6. Morrison SL, Johnson MJ, Herzenberg LA. Chimeric human antibody molecules: mouse antigenbinding domain human constant region domain. Proc Natl Acad Sci USA. 1984;81:6581-855.
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med. 2001;344:783-92.
8. Bertram HC, Check IJ, Milano MA. Immunophenotyping large B-cell lymphomas. Flow cytometric pitfalls and pathologic correlation. Am J Clin Path. 2001;116:191-203.
9. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med. 2008;359:613-26.
10. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose, 22-day treatment program. J Clin Oncol. 1998;16:2825-33.
11. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999;10:655-61.
12. Czuczman MS, Grillo-Lopez AJ, White CA, et al. The treatment of patients with low-Grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody (Rituxan, Rituximab) and CHOP chemotherapy. J Clin Oncol. 1999;17:268-76.
13. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235-42.
14. Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711-6.
15. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 2005;23:694-704.
16. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-32.
17. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B-cell by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644-52.
18. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B-cells. Cancer Immunol Immunother. 2000;48:673-83.
19. Popoff IJ, Savage JA, Blake J, et al. The association between CD20 and Src-family tyrosine kinases requires an additional factor. Mol Immunol. 1998;35:207-14.
20. Walshe CD, Beers SA, French RR, et al. Induction of cytosolic calcium flux byCD20 is dependent upon B-Cell antigen receptor signaling. J Biol Chem. 2008;25:16971-84.
21. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: Src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis. 2000;26:133-43.
22. Daniels I, Abulayha AM, Thomson BJ, Haynes AP. Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis. 2006;11:1013-23.
23. Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak SH, et al. The BH3-mimetic obatoclax (GX15-070) posses a dual-mechanism-of-action and induces both apoptosis and autophagy-dependent cell death of B-cell non-Hodgkin's lymphoma (B-NHL) cells. Blood. 2008;112(11):605a.
24. Gruber EA, Czuczman MS, Olejniczak SH, Knight J, Hernandez-Ilizaliturri FJ. GX15-070 and bortezomib induce up-regulation of BH3 single domain pro-apoptotic proteins puma and noxa and is associated with synergistic anti-tumor activity in rituximab-sensitive, rituximab-resistant cell lines (RSCL and RRCL), and primary lymphoma patient specimens. Blood. 2007;110:1389a.
25. Olejniczak S, Hernandez-Ilizaliturri FJ, Blickwedehl J, et al. Bortezomib induces a pro-apoptotic Bcl-2 family protein expression profile necessary to kill therapy-resistant B cell non-Hodgkin's lymphoma (B-NHL). AACR Meet Abstr. 2008;4383.
26. Stel AJ, Ten Cate B, Jacobs S, et al. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fasinduced apoptosis. J Immunol. 2007;178:2287-95.
27. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443-6.
28. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-8.
29. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940-7.
30. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003;48:455-9.
31. Treon SP, Hansen M, Branagan AR, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol. 2005;23:474-81.
32. Congy-Jolivet N, Probst A, Watier H, et al. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit Rev Oncol Hematol. 2007;64:226-33.
33. Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90:1109-14.
34. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004;64:4664-9.
35. Hatjiharissi E, Xu L, Santos DD, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007;110:2561-4.
36. Galimberti S, Palumbo GA, Caracciolo F, et al. The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms. J Chemother. 2007;19:315-21.
37. Carlotti E, Palumbo GA, Oldani E, et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica. 2007;92:1127-30.
38. Mitrovic Z, Aurer I, Radman I, et al. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica. 2007;92:998-9.
39. Kim DH, Jung HD, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006;108:2720-5.
40. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res. 2003;9:5866-73.
41. Binyamin L, Alpaugh RP, Hughes TL, et al. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol. 2008;180:6392-401.
42. Hernandez-Ilizaliturri FJ, Jupudy V, Reising S, et al. Concurrent administration of granulocyte colonystimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leuk Lymphoma. 2005;46:1775-84.
43. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005;11:5984-92.
44. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the antitumour activity of rituximab in vivo. Br J Haematol. 2008;140:36-45.
45. Niitsu N, Hayama M, Okamoto M, et al. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma. Clin Cancer Res. 2004;10:4077-82.
46. Van der Kolk LE, Grillo-Lopez AJ, Baars JW, et al. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia. 2003;17:1658-64.
47. Van der Kolk LE, de Haas M, Grillo-Lopez AJ, et al. Analysis of CD0-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia. 2002;16:693-9.
48. Cartron G, Zhao-Yang L, Baudrad M, et al. Granulocyte-macrophage colony-Stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a Phase II study. J Clin Oncol. 2008;26:2725-31.
49. McLaughlin P, Liu N, Poindexter N, et al. Rituximab plus GM-CSF (Leukine) for indolent lymphoma. Ann Oncol. 2005;16:68.
50. Leidi M, Gotti E, Bologna L, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than M1 cells in vitro. J Immunol. 2009;182:4415-22.
51. Shimadoi S, Takami A, Kondo Y, et al. Macrophage colony-stimulating factor enhances rituximab-dependent cellular cytotoxicity by monocytes. Cancer Sci. 2007;98:1368-72.
52. Albertsson PA, Basse PH, Hokland M, et al. NK cells and the tumor microenvironment: implications for NK cell function and anti-tumour activity. Trends Immunol. 2003;24:603-9.
53. Berinstein N, Levy R. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2. J Immunol. 1987;139:971-6.
54. Berinstein N, Starnes CO, Levy R. Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2. J Immunol. 1988;140:2839-45.
55. Khan KD, Emmanouilides C, Benson DM, et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clin Cancer Res. 2006;12:7046-53.
56. Berdeja JG, Hess A, Lucas DM, et al. Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res. 2007;13:2392-9.
57. Ansell SM, Witzig TE, Kurtin PJ, et al. Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002;99:67-74.
58. Ansell SM, Geyer SM, Maurer GM, et al. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clin Cancer Res. 2006;12:6056-63.
59. Castermans K, Tabruyn S, Zeng R, et al. Angiostatic activity of the antitumor cytokine interleukin-21. Blood. 2008;112:4940-7.
60. Gowda A, Roda J, Hussain S, et al. IL-21 mediates apoptosis through up regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood. 2008;111:4723-30.
61. Moga E, Alvarez E, Canto E, et al. NK cells stimulated with IL-15 or CpG ODN enhance rituximabdependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol. 2008;36:69-77.
62. Wu L, Adams M, Carter T. Lenalidomide enhances natural killer cell and monocyte-mediated antibodydependent cellular cytotoxicity of rituximab-treated CD20? tumor cells. Clin Cancer Res. 2008;14:4650-7.
63. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145:344-9.
64. Chanan-Khan A, Miller K, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II Study. J Clin Oncol. 2006;24:5343-9.
65. Mori K, Lida S, Yamane-Ohnuki N, et al. Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies. Cytotechnology. 2007;55:109-14.
66. Lida S, Misaka H, Inoue M, et al. Nonfucosylated therapeutic IgG1antibody can evade the inhibitory rffect of derumImmunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to Fc:RIIIa. Clin Cancer Res. 2006;12:2879-87.
67. Iida S, Kuni-Kamochi R, Mori K, et al. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer. 2009;9:58.
68. Niwa R, Kobayashi Y, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res. 2005;11:2327-36.
69. Stanglmaier M, Faltin M, Ruf P, et al. Bi20 (FBTA05), a novel trifunctionalbispecific antibody (anti-CD20 3 anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer. 2008;123:1181-9.
70. Gall JM, Davol PA, Grabert RC, et al. T-cells armed with anti-CD3 9 anti-CD20 bispecific antibody enhance killing of CD20 + malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol. 2005;33:452-9.
71. Li B, Shu Shi S, Qian W, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res. 2008;68:2400-8.
72. Rossi EA, Goldenberg DM, Cardillo TM, et al. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008;68:8384-92.
73. Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin's lymphomas. Blood. 2002;101:949-54.
74. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated celllysis. Blood. 2000;95:3900-8.
75. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008;20:444-9.
76. Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, et al. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk Lymphoma. 2007;48:2424-36.
77. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol. 2001;114:800-9.
78. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177:362-71.
79. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111:5486-95.
80. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111:1094-100.
81. Ziller F, Macor P, Bulla R, et al. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement regulatory proteins CD55 and CD59. Eur J Immunol. 2005;35:2175-83.
82. Macor P, Tripodo C, Zorzet S, et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res. 2007;67:10556-63.
83. Peng W, Zhang X, Mohamed N, et al. A deImmunizedchimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation. Cancer Immunol Immunother. 2005;54:1172-9.